Author: Thibaud, Santiago; Tremblay, Douglas; Bhalla, Sheena; Zimmerman, Brittney; Sigel, Keith; Gabrilove, Janice
Title: Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVIDâ€19 Cord-id: 2fyouaol Document date: 2020_6_4
ID: 2fyouaol
Snippet: Severe cases of coronavirus disease 2019 (COVID-19) are usually accompanied by an exuberant immune response comparable to cytokine release syndrome (CRS), with markedly elevated serum levels of proinflammatory cytokines which are thought to be a major drivers of morbidity and mortality for these patients (Huang, et al 2020). Several drugs with anti-inflammatory properties (tocilizumab, siltuximab, sarilumab, anakinra, among others) have been suggested as adjuncts to supportive care in the manage
Document: Severe cases of coronavirus disease 2019 (COVID-19) are usually accompanied by an exuberant immune response comparable to cytokine release syndrome (CRS), with markedly elevated serum levels of proinflammatory cytokines which are thought to be a major drivers of morbidity and mortality for these patients (Huang, et al 2020). Several drugs with anti-inflammatory properties (tocilizumab, siltuximab, sarilumab, anakinra, among others) have been suggested as adjuncts to supportive care in the management of COVID-19, and several clinical trials are underway (NCT04315298, NCT04317092, NCT04306705).
Search related documents:
Co phrase search for related documents- acalabrutinib ibrutinib and lung injury: 1, 2, 3
- acalabrutinib ibrutinib and lung injury protect: 1
- acute lung injury and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute lung injury and lung injury protect: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute lung injury and lung macrophage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
Co phrase search for related documents, hyperlinks ordered by date